|
| 36780608 | Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. | J Clin Oncol | 2023 |
| 36241862 | Cancer care in German centers of excellence during the first 2Â years of the COVID-19 pandemic. | J Cancer Res Clin Oncol | 2023 |
| 36166093 | Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. | Clin Cancer Res | 2023 |
| 36162037 | Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). | Journal of Clinical Oncology | 2023 |
| 36401150 | Cancer Patients' Age-Related Benefits from Mobile Neurofeedback-Therapy in Quality of Life and Self-efficacy: A Clinical Waitlist Control Study. | Applied Psychophysiology Biofeedback | 2023 |
| 36382970 | Database for queries of melanoma cohorts with molecular and clinical data. | Pigment Cell and Melanoma Research | 2023 |
| 37760406 | COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma. | | 2023 |
| 37675901 | The Association of HIV-Specific Risk Factors with Cardiovascular Events in Addition to Traditional Risk Factors in People Living with HIV. | | 2023 |
| 37595494 | Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp. | | 2023 |
| 37660535 | Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM. | | 2023 |
| 37827067 | Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma. | | 2023 |
| 37816303 | Proteasome inhibition potentiates Kv1.3 potassium channel expression as therapeutic target in drug-sensitive and -resistant human melanoma cells. | | 2023 |
| 37730278 | Treatment management for -mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG. | | 2023 |
| 37730278 | Treatment management for -mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG. | | 2023 |
| 37580519 | Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. | Nat Cancer | 2023 |
| 38093413 | Combined immunotherapy with ipilimumab plus nivolumab in metastatic PD-1/PD-L1-refractory Merkel cell carcinoma-a case report. | | 2023 |
| 37980855 | Deep learning based histological classification of adnex tumors. | | 2023 |
| 37880788 | The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab. | J Transl Med | 2023 |
| 37875144 | Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. | | 2023 |
| 37418389 | TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entities. | PLoS One | 2023 |
| 37212689 | Reduced Staphylococcus Abundance Characterizes the Lesional Microbiome of Actinic Keratosis Patients after Field-Directed Therapies. | | 2023 |
| 37089863 | Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence. | Cancer Res Commun | 2023 |
| 36652557 | Active Remodeling of Capillary Endothelium via Cancer Cell-Derived MMP9 Promotes Metastatic Brain Colonization. | | 2023 |
| 36585570 | One Website to Gather them All: Usability Testing of the New German SKin Cancer INFOrmation (SKINFO) Website-A Mixed-methods Approach. | | 2023 |
| 37280276 | The German Network for Personalized Medicine to enhance patient care and translational research. | Nat Med | 2023 |
| 37277264 | Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. | | 2023 |
| 37028818 | Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma. | J Immunother Cancer | 2023 |
| 37028819 | Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG. | | 2023 |
| 36773463 | Characterisation and outcome of RAC1 mutated melanoma. | | 2023 |
| 36509002 | BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes. | | 2023 |
| 37327789 | The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity. | Cancer Cell | 2023 |
| 37199727 | HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance. | Clin Cancer Res | 2023 |
| 36947734 | Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in -Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. | | 2023 |
| 37257277 | Deep learning detection of melanoma metastases in lymph nodes. | | 2023 |
| 37193799 | Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. | Nat Med | 2023 |
| 37006279 | COVID-19 vaccination in psoriasis patients receiving systemic treatment: A prospective single-center study. | Front Immunol | 2023 |
| 37004702 | The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma. | | 2023 |
| 36478190 | Advancements in melanoma cancer metastasis models. | | 2023 |
| 37315536 | Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer TÂ cell responses. | | 2023 |
| 37315382 | Deep learning in computational dermatopathology of melanoma: A technical systematic literature review. | | 2023 |
| 36693381 | Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. | Med | 2023 |
| 37309702 | COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF. | Future Oncol | 2023 |
| 37245442 | Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG. | | 2023 |
| 36691908 | Neurofeedback Treatment Affects Affective Symptoms, But Not Perceived Cognitive Impairment in Cancer Patients: Results of an Explorative Randomized Controlled Trial. | | 2023 |
| 37432641 | Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial. | | 2023 |
| 36930373 | Changes in body mass index, weight, and waist-to-hip ratio over five years in HIV-positive individuals in the HIV Heart Aging Study compared to the general population. | | 2023 |
| 36681612 | Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma. | | 2023 |
| 36680880 | Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma. | | 2023 |
| 36606548 | Multispectral optoacoustic tomography to differentiate between lymph node metastases and coronavirus-19 vaccine-associated lymphadenopathy. | | 2023 |
| 37167764 | Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial. | Eur J Cancer | 2023 |